Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Simple item page
dc.contributor.authorDesta, Zeruesenay
dc.contributor.authorGammal, Roseann S.
dc.contributor.authorGong, Li
dc.contributor.authorWhirl-Carrillo, Michelle
dc.contributor.authorGaur, Aditya H.
dc.contributor.authorSukasem, Chonlaphat
dc.contributor.authorHockings, Jennifer
dc.contributor.authorMyers, Alan
dc.contributor.authorSwart, Marelize
dc.contributor.authorTyndale, Rachel F.
dc.contributor.authorMasimirembwa, Collen
dc.contributor.authorIwuchukwu, Otito F.
dc.contributor.authorChirwa, Sanika
dc.contributor.authorLennox, Jeffrey
dc.contributor.authorGaedigk, Andrea
dc.contributor.authorKlein, Teri E.
dc.contributor.authorHaas, David W.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2021-08-09T19:06:09Z
dc.date.available2021-08-09T19:06:09Z
dc.date.issued2019-04-21
dc.description.abstractThe human immunodeficiency virus (HIV) type-1 non-nucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by CYP2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationDesta, Z., Gammal, R. S., Gong, L., Whirl-Carrillo, M., Gaur, A. H., Sukasem, C., Hockings, J., Myers, A., Swart, M., Tyndale, R. F., Masimirembwa, C., Iwuchukwu, O. F., Chirwa, S., Lennox, J., Gaedigk, A., Klein, T. E., & Haas, D. W. (2019). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clinical Pharmacology & Therapeutics, 106(4), 726–733. https://doi.org/10.1002/cpt.1477en_US
dc.identifier.issn1532-6535en_US
dc.identifier.urihttps://hdl.handle.net/1805/26401
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/cpt.1477en_US
dc.relation.journalClinical Pharmacology & Therapeuticsen_US
dc.sourcePMCen_US
dc.subjectCYP2B6en_US
dc.subjectefavirenzen_US
dc.subjectHIVen_US
dc.subjectAIDSen_US
dc.subjectpharmacogeneticsen_US
dc.subjectpharmacogenomicsen_US
dc.subjectCPICen_US
dc.subjectpharmacokineticsen_US
dc.subjectCNS toxicityen_US
dc.subjectmetabolismen_US
dc.titleClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nihms-1025066.pdf
Size:
302.04 KB
Format:
Adobe Portable Document Format
Description:
Author's manuscript
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works